Adding TARE before atezolizumab-bevacizumab improves survival in advanced HCC

Sequential TARE then atezolizumab/bevacizumab improved OS in advanced HCC (median 14.1 vs 6.4 months, HR 0.43, p<0.001) in a retrospective 156-patient study.

• Propensity score matching and inverse probability of treatment weighting were used to balance baseline characteristics.
• Survival benefit was most pronounced in patients with Child-Pugh class A (OS: 14.6 vs 7.1 months) or ALBI grade 1 (OS: 21.4 vs 8.3 months; PFS: 8.1 vs 5.7 months).

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.